Outpatient metrizamide myelography: prospective evaluation of safety and cost effectiveness.
A group of 228 consecutive patients undergoing metrizamide myelography was prospectively evaluated for postprocedure symptoms. The observed prevalence of these symptoms concurs with previously reported inpatient studies, with the most common sequelae being exacerbation or onset of spine or extremity pain, headache, nausea, and paresthesia. Limitation of administered dose of metrizamide in lumbar myelography may slightly reduce the occurrence of common symptoms, but withdrawal of contrast medium at the completion of examination had no impact on their occurrence. There was a higher occurrence of paresthesia in cervical myelography, but otherwise there was no significant difference in symptoms between cervical and lumbar studies. Outpatient metrizamide myelography can be performed with relative safety with the potential for significant cost savings.
Badami
J P
JP
Baker
R A
RA
Scholz
F J
FJ
McLaughlin
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000191:economics; D003362:Cost-Benefit Analysis; D005069:Evaluation Studies as Topic; D006801:Humans; D008161:Lumbosacral Region; D008793:Metrizamide / Q000009:adverse effects; D008875:Middle Aged; D009192:Myelography / Q000009:adverse effects / Q000191:economics; D009333:Neck; D011446:Prospective Studies
D008793:Metrizamide